GlassScriptPhysician profile
Tiffany D Brown
NPI 1023201555
$2,615.69
in general payments reported to CMS, 2019-2025
9 companies · $511 in 2025
The $511 reported for 2025 was more than what 78% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.40 · 2020: $48.26 · 2021: $199 · 2022: $81.79 · 2023: $198 · 2024: $1,482 · 2025: $511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,157 · Travel and Lodging: $1,034.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,157.25 |
| Travel and Lodging | $1,033.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,460.21 | 2024 | Precision 1 |
| Johnson & Johnson Vision Care, INC. | $275.78 | 2021-2023 | Acuvue |
| Sight Sciences, INC. | $203.23 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $147.57 | 2025 | Miebo |
| Tarsus Pharmaceuticals, INC. | $146.25 | 2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $143.66 | 2019-2020 | |
| Harrow Eye, LLC | $133.15 | 2025 | Vevye |
| Glaukos Corporation | $84.34 | 2025 | Idosetr |
| Oyster Point Pharma, INC. | $21.50 | 2024 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.